Table 4.
Cox Proportional Hazards Model Comparing 5-year Overall Survival by Disease Subtype, 2010 to 2015, According to Clinical Disease Stage and Initial Treatment Strategy
| Variable | DCIS |
NET |
Primary operation |
|||
|---|---|---|---|---|---|---|
| ER+ | ER– | cT1N0 | cT2N0 | cT1N0 | cT2N0 | |
| Median follow-up time, mo | 41.6 | 42.4 | 33.7 | 36.3 | 40.1 | 40.9 |
| Time to operation | ||||||
| < 60 d | 98.1 | 97.0 | 94.6 | 87.8 | 96.7 | 92.6 |
| 61–120 d | 97.9 | 96.8 | 97.6 | 91.8 | 95.8 | 91.8 |
| > 120 d | 97.4 | 96.6 | 96.9 | 91.5 | 94.7 | 90.8 |
| p Value timing | 0.085 | 0.669 | 0.129 | 0.538 | < 0.001 | 0.046 |
Adjusted for age, race, Charlson Comorbidity Index score, insurance, region, grade, histology, operation type, path T/N, adjuvant therapy.
DCIS, ductal carcinoma in situ; ER, estrogen receptor; NET, neoadjuvant endocrine therapy.